

# Molecular Biology

**Entry Clone Accession:** IMAGE:4719195

**Entry Clone Source:** MGC

**SGC Construct ID:** RG9MTD1A-c113

**Protein Region:** Q203-T403

**Vector:** pNIC-CTHF

**Tag:** C-TEV;C-6HIS

**Host:** BL21(DE3)-R3-pRARE2

## Sequence (with tag(s)):

MQPLVFD MAYENYMKRKELQNTVSQ LLESEGWNRRNVD PPHIYFCNLKIDGALHREL V  
KRYQEKWDKLLLTSTEKSHVDLFPKDSIIYLTADSPNVM TTFRHDKVYVIGSFVDKSMQP  
GTSLAKAKRLNLATECLPLDKYLQWEIGNKNLTLDQMIRILLCLKNNGNWQEALQFVPK  
RKHTGFLEISQHSQEFINRLKKAKTAENLYFQSHHHHHHDYKDDDDK

## Sequence after tag cleavage:

MQPLVFD MAYENYMKRKELQNTVSQ LLESEGWNRRNVD PPHIYFCNLKIDGALHREL V  
KRYQEKWDKLLLTSTEKSHVDLFPKDSIIYLTADSPNVM TTFRHDKVYVIGSFVDKSMQP  
GTSLAKAKRLNLATECLPLDKYLQWEIGNKNLTLDQMIRILLCLKNNGNWQEALQFVPK  
RKHTGFLEISQHSQEFINRLKKAKTAENLYFQ

## DNA Sequence:

CTTAAGAAGGAGATATACTATGCAACCTTTGGTTTTTGACATGGCTTACGAAAATTATA  
TGAAACGAAAAGAATTGCAGAATACTGTTTCCCAGCTTTTAGAAAAGTGAAGGATGGA  
ACAGAAGAAATGTTGATCCTTTCCATATTTATTTCTGCAATCTAAAAATAGATGGTGCTT  
TGCACAGAGAGTTAGTTAAACGGTATCAAGAAAAATGGGACAAATTGCTTTTAACATC  
AACAGAAAAGTCTCATGTAGATTTATTTCCAAAGGACAGTATTATCTATTTAAGTGCAG  
ATTCTCCCAATGTTATGACTACTTTTCAGGCATGACAAAGTTTATGTAATTGGGTCTTTTG  
TTGATAAGAGTATGCAGCCAGGCACATCCCTAGCCAAGGCAAAACGGCTGAACCTGG  
CAACTGAATGCCTTCCATTAGATAAATATTTACAATGGGAAATTGGTAACAAAAATCTC  
ACCTTAGATCAAATGATACGTATTTTGTTATGTCTGAAAAACAATGGTAATTGGCAAGA  
GGCTCTGCAATTCGTTCCCAAGAGAAAACATACTGGTTTTCTGGAGATTTCTCAGCAT  
TCTCAAGAGTTTATCAACAGACTAAAGAAGGCAAAGACTGCAGAGAACCTCTACTTC  
CAATCGCACCATCATCACCACCATGATTACAAGGATGACGACGATAAGTGAGGATCC

# Protein Expression

**Medium:** Terrific Broth

**Antibiotics:** Kanamycin

**Procedure:** Plasmids were transformed into *E. coli* BL21(DE3)-R3-pRARE2 competent cells, cultured in Terrific Broth at 37°C, and induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside for overnight growth at 18°C.

# Protein Purification

## Buffers:

Lysis buffer: 500 mM NaCl, 50 mM HEPES pH 7.5, 5% glycerol, 0.5 mM TCEP, 20 mM imidazole

Wash buffer: 500 mM NaCl, 50 mM HEPES pH 7.5, 5% glycerol, 0.5 mM TCEP, 40 mM imidazole

Elution buffer: 500 mM NaCl, 50 mM HEPES pH 7.5, 5% glycerol, 0.5 mM TCEP, 250 mM imidazole

SEC buffer: 500 mM NaCl, 50 mM HEPES pH 7.5, 5% glycerol, 0.5 mM TCEP

### **Procedure:**

#### *Cell lysis*

Frozen cell pellets were thawed and resuspended on ice in 50 mL lysis buffer containing 1 mL protease inhibitor cocktail set III (Calbiochem) per L of harvested cell culture. The cells were lysed by passing five times on a homogeniser (EmulsiFlex-C5-Avestin) to a pressure of 1000 bar. The cell lysate was clarified by centrifugation (Beckman Coulter Avanti JXN-26) at 4°C for 1 h at 16500 rpm.

#### *Immobilised metal affinity chromatography (IMAC)*

Clarified lysate from large-scale extraction was added with 2 mL of Ni-NTA affinity resin (GE Healthcare) and incubated at 4°C for 1 h rotating at 8 rpm. The lysate, together with Ni-NTA resin, was centrifuged (Beckman Coulter Avanti JXN-26) for 30 min at 5000 rpm at 4°C. The Ni-NTA pellet was applied onto a 1.5x10 cm (DxH) column (Bio-Rad) under gravity flow and the flow-through was collected for SDS-PAGE analysis. The Ni-NTA resin was washed with 2 x 10 CVs Lysis buffer and 2 x 10 CVs Wash buffer. The bound protein was eluted with 5 x 2 CVs of Elution buffer.

#### *Size exclusion chromatography (SEC)*

Pooled fractions from IMAC were concentrated to 5 mL using an Amicon Ultra centrifugal filter device (Merck Millipore) with a 10 kDa cut-off. The concentrated sample was loaded onto a 120 mL Sephadex 75 HiLoad 16/60 column connected to an AKTA-Express (GE Healthcare) in 4°C. Before loading the protein, the column was pre-equilibrated with SEC buffer. Protein was loaded and eluted at a rate of 1 mL/min and 1.8 mL fractions were collected throughout the run.

#### *Treatment with Tobacco etch virus protease*

To remove the affinity tag from target proteins, Tobacco etch virus (TEV) protease was added to the eluates in a 1:20 (w/v) protease-to-protein ratio and the mixture was incubated overnight at 4°C.

#### *Reverse IMAC*

TEV protease-treated sample was applied to a 2x10 cm gravity column containing 125 µL Ni-NTA affinity resin (GE Healthcare) equilibrated with Lysis buffer. The Ni-NTA resin was washed with 2 x 8 CVs Binding buffer and 2 x 8 CVs Wash buffer. Fractions containing protein were pooled.

**Concentration:** 10.93 mg/ml

**Mass-spec Verification:** Expected mass of the construct confirmed

## **Structure Determination**

**Crystallization:** Crystals of hMRPP1<sub>MT</sub> were grown by vapour diffusion at 4°C, from sitting drops mixing 200 nL of protein (11 mg/ml; pre-incubated with 4.8 µM SAM) and 100 nL of reservoir solution containing either 14% PEG 1000, 28% glycerol or 12% PEG 1000, 28% glycerol, 1.5%(w/v) PEG 3350. Crystals were cryo-protected with reservoir solution supplemented with 25% (v/v) propylene glycol, and flash-cooled in liquid nitrogen. Heavy atom-derivatised crystals were obtained by soaking with 10mM C<sub>9</sub>H<sub>9</sub>HgNaO<sub>2</sub>S for 1h10min.

**Data Collection:** Diffraction data were collected on the Diamond Light Source beamline I04-1 for the HA-soaked crystals to 2.49 Å, and for two crystals of the as-purified protein to 2.22 Å and 1.96 Å.

**Data Processing:** Phases were determined by single-wavelength anomalous dispersion (SAD) with the SHELX package using the HA dataset. The phases from the HA-dataset were combined with the 2.22 Å native dataset, and the model was built in COOT. This model was used as search model in a molecular replacement done in PHASER from the CCP4 Suite using the native data collected to 1.96 Å. Modelling and refinement were carried out using Refmac and COOT.